Xorte logo

News Markets Groups

USA | Europe | Asia | World| Stocks | Commodities



Add a new RSS channel

 
 


Keywords

2025-08-07 19:30:00| Fast Company

Shares of Intel dropped more than 3% Thursday after President Donald Trump demanded the immediate resignation of the chipmakers CEO. Claiming that there is no other solution to this problem, Trump said Lip-Bu Tan is highly conflicted in an early-morning post on Truth Social. Though the president didnt elaborate on his reasoning, Reuters has previously reported that Tan, either directly or through venture funds, has invested at least $200 million in Chinese manufacturing and chip companies. Intel shares dropped as much as 3.5% before recovering some of those losses. Tan caught the ire of Trump one day after Sen. Tom Cotton, a Republican from Arkansas, called Tans ties to Chinese firms concerning and questioned the potential impact on U.S. national security in a letter he sent to Frank Yeary, Intels board chair. In his letter, Cotton requested that Yeary respond by next week to questions about Tans ties to Chinese firms and his prior tenure as CEO of Cadence Design Systems, which last month agreed to plead guilty in a past criminal case. He also cited Intels receipt of nearly $8 billion in funding under the CHIPS and Science Act during Joe Bidens presidency last year. Intel is required to be a responsible steward of American taxpayer dollars and to comply with applicable security regulations, Cotton wrote. Mr. Tans associations raise questions about Intels ability to fulfill these obligations. TAN AND TRUMP Tans past investments came under scrutiny following his appointment as Intel’s CEOalthough as a former venture capitalist, the size and scope are perhaps not so unusual. A Reuters investigation found that Tans investments in China were made through Walden International, the venture capital firm he founded in 1987, along with two Hong Kong-based holding companies. Reuters said it found no evidence that Tan was invested directly in any company thats banned by the U.S. Treasurys Chinese Military-Industrial Complex Companies List. Whats more, Walden International wasnt an anomaly: It was one of five American venture capital firms that were the subject of a congressional investigation last year into investments in Chinas semiconductor industry that have totaled $1 billion since 2001. The other funds on the list were GGV Capital, GSR Ventures, Qualcomm Ventures, and Sequoia Capital.  But Walden Internationaland Tanmay be out of favor with the Trump administration for other reasons. GGV Capital split its U.S. and China operations into two firms last year, while GSR Ventures did so this year. Qualcomm donated $1 million to a nonprofit that supported Trumps 2024 election bid, while Shaun Maguire, one of Sequoias partners, is a vocal Trump supporter and the firm has ties to David Sacks, the White House AI and crypto czar. As recently as March, Tan said the Trump administration was prepared to help Intel so the U.S. can maintain semiconductor leadershipand he would seek the administrations help, as needed. On Wednesday, Trump threatened a 100% tariff on imported semiconductors and chips, which would actually favor Intel, as it has domestic facilities.  Even if information about Tans investments is known, its trickier to track the personal investments of CEOs in foreign companies, as theyre not required to disclose that information unless theres a potential conflict of interest. But sometimes their investments do catch the eye of watchdogs. Last year, for example, Campaign for Accountability, a Washington, D.C.-based nonprofit that runs the Tech Transparency Project, reported that former Google CEO Eric Schmidt had invested nearly $17 million through his private foundation into the Chinese AI industry, even as he was leading the National Security Commission on Artificial Intelligence.  INTELS WOES The Santa Clara, California-based company issued a statement in response on Wednesday, saying: Intel and Tan are deeply committed to the national security of the U.S. and the integrity of our role in the U.S. defense ecosystem. The company hasnt responded to Trumps call for Tans immediate resignation, according to reporting by other news outlets. Tan was appointed as CEO of Intel in March, replacing Pat Gelsinger, who was forced out in late 2024 after the board of directors lost confidence in his turnaround plans for the company. In his first few months, Tan has already embarked on an aggressive plan to streamline the organization with more layoffs, to the tune of about 15%. In a July letter to employees about Intel’s second-quarter financial results, Tan said such efforts are steps in the right direction. REACTIONS TO TRUMPS POST On social media, several commenters questioned whether Intel will bend the knee and submit to Trumps call for Tans resignation. Analysts also weighed in about the implications of the presidents post. Unfortunately, unlike other tech CEOs, Lip-Bu does not appear to have cultivated the kind of personal relationship with Trump that would help to assuage his ire, Bernstein analyst Stacy Rasgon said in a note to clients.  And Trumps apparent meddling in corporate leadership could be setting a very unfortunate precedent, Phil Blancato, CEO of Ladenburg Thalmann Asset Management (which does not own Intel shares) told Reuters. You don’t want American presidents dictating who runs companies, but certainly his opinion has merit and weight.” 


Category: E-Commerce

 

LATEST NEWS

2025-08-07 19:00:00| Fast Company

Its been a week of wins for Eli Lillys weight-loss drugs. In the company’s second quarter earnings report on Thursday, it reported that sales of Mounjaro, its type-2 diabetes medication often used for weight loss, reached nearly $5.2 billion in revenue, up 68% from the same quarter last year and exceeding analyst estimates of $4.7 billion. Similarly, its weight-loss medication Zepbound reached $3.4 billion in sales, up 172% year-over-year and exceeding estimates of $3 billion. According to Eli Lilly, the company’s market share for the class of drugs that includes Mounjaro and Zepbound increased to 57% during the quarter. Additionally, Mounjaro demonstrated its ability to protect cardiovascular health in trial results announced July 31. And the company also on Thursday announced its oral GLP-1, orforglipron, helped patients lose an average of 27.3 pounds in a phase three clinical trial. These successes, along with high demand for its weight-loss drugs, led Eli Lilly to increase its 2025 guidance. Still, investors are wary of the 148-year-old pharmaceutical company. Eli Lilly (NYSE: LLY) stock fell over 14% today, dropping to its lowest price in over a year. Meanwhile, Eli Lillys key competitor in the weight-loss sphere, Novo Nordisk, saw its shares surge more than 7%, even after a disappointing earnings report yesterday suggested lower growth expectations as Wegovy and Ozempic face mounting competition from the cheaper Eli Lilly alternatives. The seemingly counterintuitive investor reactions come down to Eli Lillys recent clinical trial testing the efficacy of its oral GLP-1, in a group of 3,127 adults who are obese or overweight and experiencing weight-related medical issues. The drug is effective. At the highest dose, over half of patients in the trial saw at least a 10% reduction in weight and nearly 40% saw at least a 15% reduction. However, investors were hoping for higher levels of weight loss to compete with Novo Nordisks medicationsincluding an oral verson of Wegovy that is up for FDA approval later this year. After Eli Lilly’s trial results were released, David Risinger, an analyst at Leerink Partners, downgraded Eli Lillys stock and changed his expectation for sales of the drug from $21.6 billion to $13.5 billion. In the increasingly crowded and fast-changing weight-loss drug space, Eli Lilly and Novo Nordisk are slated to remain in close competition. Eli Lilly plans to move to a second phase three trial for its oral GLP-1, while Novo Nordisks pill version of Wegovy also continues its path to FDA approval.


Category: E-Commerce

 

2025-08-07 17:30:45| Fast Company

OpenAI on Thursday unveiled its highly anticipated GPT-5, a powerful multi-modal AI model featuring major advancements in problem-solving and coding. The new flagship model was announced during a Thursday morning livestream. Unlike previous releases that were limited to paid subscribers, GPT-5 will be available to free-tier ChatGPT users as well, OpenAI said. OpenAI CEO Sam Altman described interacting with the new model as akin to conversing with a PhD-level expert, noting that while GPT-3 was comparable to a high school student and GPT-4 to a college student, With GPT-5 you get an entire team of PhD experts in your pocket, ready to help you, Altman said. During the announcement, OpenAI researchers emphasized that GPT-5 was designed to be more reliable and accurate, with fewer hallucinations. GPT-5 offers improvements in reasoning, higher-quality code generation, greater autonomy with reduced need for user input, and seamless integration with platforms like ChatGPT and Google’s Gmail and Calendar apps. Earlier language models relied only on pretraining to generate responses. GPT-5, like recent inference-based models, can also incorporate new data from user prompts in real time (a method known as test-time computing). This release also unifies OpenAIs model naming, replacing names like o1 and o4-mini with the GPT-5 family, signaling a shift to models that combine both pretraining and inference. For many, the key question is whether the leap from GPT4 to GPT-5 will prove as dramatic as the jump from GPT3 to GPT4. Independent testing will shed light on that. OpenAI also recently introduced two open-weight modelsgpt-oss-120b and gpt-oss-20bwhich are freely available and modifiable by developers. This move marked a rare shift from its typically closed model strategy. However, with GPT-5, OpenAI returns to its more traditional closed approach. In addition, the company announced a partnership with the U.S. federal government to provide executive branch agencies access to its enterprise-grade chatbot. Through a landmark agreement with the General Services Administration (GSA), ChatGPTEnterprise will be made available to agencies for just $1 per agency for one year. OpenAI has assured that it will not use government data to train its AI models.


Category: E-Commerce

 

Latest from this category

08.08Profits over people and microplastics in every meal?
08.08How Formula E made EV racing a global phenomenon
07.08Cryptos real barrier isnt trust, its understanding
07.08Successful companies will integrate AI training into workflow
07.08TikTok is losing it over real-life octopus cities
07.08The Trump administration cant win its flame war with South Park
07.08Duolingo wants to make its music lessons more addictive
07.08Why is Trump going after Intels CEO?
E-Commerce »

All news

08.08Are accrual strategies the new key to success in fixed income investing?
08.08What US consumers can expect from new tariffs on imported goods
08.08Indian Continent Investment to sell 0.8% stake in Bharti Airtel for Rs 9,300 crore
08.08Tata & SP Group reignite exit talks after years: Chandrasekaran meets Mistry in first formal contact since relations soured in 2016
08.08Can US-Russia summit alleviate India's concerns over Trump's tariff policies?
08.08President Trump defends the US economy with charts after jobs report showed warning signs
08.08Why firms are merging HR and IT departments
08.08Later, closer, shorter - the holidays Britons are booking this summer
More »
Privacy policy . Copyright . Contact form .